Edge Therapeutics, Inc. (NASDAQ:EDGE) has market worth of 466.24M along 28.24M outstanding shares. The stock moved 0.67% to $16.62 in recent session. The recent traded volume was 54980 shares. The stock had closed at $16.51 on the previous day.
Presently Insiders holds 2.10% of Edge Therapeutics, Inc. shares. Institutional Owners keep 49.50% stake of company’s shares. The net percent change held by Institutional Investors has seen a change of -2.52%over last three month period. The net percent change kept by insiders has seen a change of -10.34%.
In the company’s insider trading activities, Macdonald R. Loch; Chief Scientific Officer of Edge Therapeutics, Inc. sold 2500 shares worth of $41300 in a transaction on 21 Mar 2018. In this transaction, these shares were sold at value of $16.52 per share, according to the information disclosed by the Securities and Exchange Commission in a Form 4 filing on 21 Mar 2018.
Macdonald R. Loch; Chief Scientific Officer of Edge Therapeutics, Inc. sold 5000 shares worth of $82350 in a transaction dated on 20 Mar 2018. Shares were sold at the average price of 16.47 per share, according to SEC Form 4 filing submitted on 21 Mar 2018.
In other transaction, Macdonald R. Loch (Chief Scientific Officer) sold 2500 shares on 19 Mar 2018 worth of $41650. In this Insider Trading activity, shares were sold with per share cost of $16.66.
Leuthner Brian A (President and CEO) of EDGE sold 2500 shares worth of $37700 at the average price of $15.08 on02 Mar 2018.
On 01 Mar 2018, Leuthner Brian A (President and CEO) sold 2500 shares at per share price of $14.81 with total value of $37025.
Edge Therapeutics, Inc. (NASDAQ:EDGE) stock has recorded a weekly performance of 0.79% and monthly performance is 18.35%. Shares have moved 75.45% over the last quarter and changed 75.08% over the recent six months. The shares registered yearly performance at 96.55% and YTD move seen at 76.20%. Return on assets come to -50.00% and Return on equity come to -67.80%.